YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Odyssey Therapeutics Inc BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients s…
On August 4, Odyssey Therapeutics (NASDAQ:ODTX) reported its second-quarter financial results and gave investors a fresh look at where its lead autoimmune drug candidate stands. The clinical-stage biopharmaceutical company said it closed t…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second…
(RTTNews) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports. Bioventus Inc. (BVS) Bioventus is a medical device company that focuses on technology for pain management an…
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec…
June 18 (Reuters) - Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering. The Princeton, New Jersey-based company's shares opened at…
(RTTNews) - Odyssey Therapeutics, Inc. (ODTX) reported on Wednesday its first quarter 2026 financial results and highlighted key clinical milestones. Company Profile Odyssey Therapeutics is a clinical-stage biopharmaceutical company develo…
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with n…
[Wall Street New York stock exchange stock market] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…
[IPO Buzzword Cubes] Clinical-stage biotech Odyssey Therapeutics (ODTX [https://seekingalpha.com/symbol/ODTX]) and neurostimulation device company Mobia Medical (MOBI [https://seekingalpha.com/symbol/MOBI]) traded sharply lower following t…
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by devel…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Odyssey Therapeutics, a maker of medicines for autoimmune disorders, has brought in $279 mill…